Research & Development

Akcea to license investigative antisense therapy AKCEA-ANGPTL3-LRx to Pfizer

Akcea Therapeutics, a majority-owned affiliate of Ionis Pharmaceuticals, has signed an agreement to license investigative antisense therapy AKCEA-ANGPTL3-LRx to pharmaceutical company Pfizer.

Johnson & Johnson to invest $500m to end HIV and tuberculosis

Johnson & Johnson has unveiled plans to invest over $500m in the next four years to help end the epidemics of HIV and tuberculosis (TB).

Icosavax launches with $51m Series A financing to advance computationally designed VLP vaccines

Icosavax announced the launch of the company with a $51 million Series A financing, led by Qiming Venture Partners USA and joined by Adams Street Partners, Sanofi Ventures and NanoDimension, with continuing support from its seed investors.

Goldfinch Bio, Takeda sign deal for CB1 monoclonal antibody to treat rare and metabolic kidney diseases

Goldfinch Bio, a U.S.-based, clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced it entered into a license agreement with Takeda Pharmaceutical Company Limited (“Takeda”) for worldwide rights to a preclinical, peripherally-restricted cannabinoid receptor 1 (CB1) monoclonal antibody.

Elicio Therapeutics completes $33m Series B Financing

Elicio Therapeutics, a next generation immuno-oncology company, announced today that it has closed its $33 million Series B financing.

Lantheus to acquire oncology company Progenics Pharmaceuticals

Lantheus Holdings has signed an agreement to acquire oncology company Progenics Pharmaceuticals in an all-stock transaction.

Sobi to buy Dova Pharmaceuticals in $915m deal

Swedish Orphan Biovitrum (Sobi) has agreed to acquire Dova Pharmaceuticals in a deal valued at around $915m.

Blade Therapeutics expands anti-fibrotic pipeline with acquisition of ATXCo and its autotaxin inhibitor

Blade Therapeutics, a biopharmaceutical company advancing novel anti-fibrotic therapies, today announced the acquisition of ATXCo, Inc., including its core asset, PAT-409, a Phase I ready autotaxin inhibitor for patients with fibrotic diseases.

Amphivena closes $62m Series C financing to expand clinical development of AMV564 into solid tumors and to develop T Cell engagement portfolio

Amphivena Therapeutics, Inc., a private clinical stage immuno-oncology company developing T cell engager therapeutics for cancer, announced today the closing of a $62 million Series C financing.